Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Research may lead to therapy that delays onset of MS symptoms

By Drug Discovery Trends Editor | March 14, 2011

Shi Hydralazine

Purdue professor Riyi Shi conducts research at his laboratory on how hydralazine affects multiple sclerosis symptoms. A provisional patent has been filed on Shi’s research, and commercialization partners are being sought. Credit: Andrew Hancock

People
suffering from multiple sclerosis may benefit if patent-pending research
conducted at Purdue
Univ. shows that a
decades-old drug approved by the FDA to treat hypertension also can delay the
onset and reduce the severity of MS symptoms.

Purdue
professor Riyi Shi is examining the effects of hydralazine on acrolein, a
compound that can affect the central nervous system and damage nerve cells.
Acrolein causes harm by reacting with the proteins and lipids that make up
cells, including neurons. Hydralazine sequesters acrolein and acrolein-protein
compounds, leading to their expulsion from the body.

“While
hydralazine was once standard therapy, it currently is not widely used to treat
hypertension because there are newer therapies available. It is reserved for
people resistant to other hypertension drugs,” said Shi, a medical doctor
and a professor of neuroscience and biomedical engineering in Purdue’s
Department of Basic Medical Sciences, School of Veterinary Medicine, Center for
Paralysis Research and Weldon School of Biomedical Engineering.

Shi’s
research focuses on discovering the effective dosage levels necessary to combat
acrolein.

“Hydralazine
usage in pediatric patients is 7.5 mg per kg of body weight, but we began testing
at a much lower ratio: 1 mg per kg of body weight, which has turned out to be
effective in delaying the onset of symptoms and lowering their severity in an
animal model of MS,” he said. “We have discovered that this dosage
level does not cause a significant blood pressure drop or other side effects
associated with using higher dosage levels for extended periods of time. We
expect that potential use in human MS patients would be at significantly lower
doses than the treatment for hypertension.”

While
results have been promising in animal testing, Shi stressed that hydralazine
therapy for MS is not yet ready for clinical usage.

Shi’s
first study, published in Neuroscience,
tested hydralazine’s effectiveness before MS symptoms developed. He plans to
follow up with studies to identify optimal treatment timing and dosage.

“We
currently are testing to see if hydralazine can reduce symptoms if treatment
starts after they begin,” he said. “If the drug continues to prove
effective, we have good reason to think it might be useful in human MS
patients.”

Shi
already has applied for a provisional patent on his research through the Purdue
Research Foundation’s Office of Technology Commercialization (OTC). The OTC
also has provided Shi with support through the Trask Innovation Fund, which
assists Purdue faculty with work to further commercial potential of
technologies disclosed to the Office of Technology Commercialization. The fund
does not support basic research but instead provides funds to reduce inventions
to practice, provide critical additional data, or develop prototypes, which
make the technology more marketable.

Shi’s
goal is to move hydralazine therapy for MS symptoms to patients, with the OTC
looking for a commercialization partner.

SOURCE


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50